Eugene I Hwang

List of Publications by Year
in descending order

58 papers	1,929 citations	361045 20 h-index	315357 38 g-index
59 all docs	59 docs citations	59 times ranked	3191 citing authors

#	Article	IF	Citations
1	Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib. Neuro-Oncology, 2022, 24, 1029-1031.	0.6	4
2	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	5.7	21
3	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. Neuro-Oncology, 2022, 24, i61-i62.	0.6	0
4	EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). Neuro-Oncology, 2022, 24, i36-i36.	0.6	0
5	IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. Neuro-Oncology, 2022, 24, i85-i86.	0.6	1
6	Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Review of Neurotherapeutics, 2021, 21, 205-219.	1.4	5
7	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTCâ€042). Pediatric Blood and Cancer, 2021, 68, e28879.	0.8	24
8	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	3.9	44
9	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. Clinical Cancer Research, 2021, 27, 2442-2451.	3.2	13
10	EMBR-08. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON â€œHEAD STARTâ€•4 CLINICAL TRIAL. Neuro-Oncology, 2021, 23, i7-i7.	0.6	0
11	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. Neuro-Oncology, 2021, 23, i6-i6.	0.6	0
12	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. Neuro-Oncology, 2021, 23, 1597-1611.	0.6	22
13	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. JAMA Oncology, 2021, 7, 1313.	3.4	61
14	The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib. Neuro-Oncology Advances, 2021, 3, vdab022.	0.4	7
15	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241.	3.9	65
16	Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. Paediatric Drugs, 2020, 22, 45-54.	1.3	7
17	Î”Np73/ETS2 complex drives glioblastoma pathogenesisâ€” targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. Neuro-Oncology, 2020, 22, 345-356.	0.6	20
18	Pediatric diffuse leptomeningeal glioneuronal tumor: Two clinical cases of successful targeted therapy. Pediatric Blood and Cancer, 2020, 67, e28478.	0.8	7

#	Article	IF	Citations
19	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. Scientific Reports, 2020, 10, 10954.	1.6	7
20	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology, 2020, 22, 773-784.	0.6	44
21	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. Pediatric Neurology, 2020, 107, 7-15.	1.0	2
22	MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii391-iii391.	0.6	2
23	EPCT-05. A PHASE I TRIAL OF THE CDK 4/6 INHIBITOR PALBOCICLIB IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR REFRACTORY CNS TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. Neuro-Oncology, 2020, 22, iii304-iii304.	0.6	0
24	MBCL-13. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON â€œHEAD STARTâ€•4 CLINICAL TRIAL. Neuro-Oncology, 2020, 22, iii390-iii390.	0.6	0
25	EPCT-16. A PHASE IB STUDY OF PTC596 IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA AND HIGH GRADE GLIOMA. Neuro-Oncology, 2020, 22, iii306-iii307.	0.6	0
26	IMMU-08. reMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET). Neuro-Oncology, 2020, 22, iii361-iii361.	0.6	0
27	EPCT-17. A PHASE I AND SURGICAL STUDY OF RIBOCICLIB AND EVEROLIMUS IN CHILDREN WITH RECURRENT OR REFRACTORY MALIGNANT BRAIN TUMORS: PEDIATRIC BRAIN TUMOR CONSORTIUM INTERIM REPORT. Neuro-Oncology, 2020, 22, iii307-iii307.	0.6	0
28	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. Neuro-Oncology, 2020, 22, iii327-iii327.	0.6	0
29	LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES. Neuro-Oncology, 2020, 22, iii371-iii371.	0.6	0
30	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. Cancer Cell, 2019, 36, 51-67.e7.	7.7	69
31	Medulloblastoma rendered susceptible to NK-cell attack by TGFÎ² neutralization. Journal of Translational Medicine, 2019, 17, 321.	1.8	32
32	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. Neuro-Oncology, 2019, 21, ii81-ii82.	0.6	0
33	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. Neuro-Oncology, 2019, 21, vi192-vi192.	0.6	0
34	QOLP-24. PATIENTSâ€™/PARENTSâ€™ EXPERIENCES OF RECEIVING OPTUNE DELIVERED TUMOR TREATMENT FIELDS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. Neuro-Oncology, 2019, 21, vi202-vi203.	0.6	1
35	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Childrenâ€™s Oncology Group ACNS0332 Trial. American Journal of Neuroradiology, 2019, 40, 1796-1803.	1.2	11
36	A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatric Blood and Cancer, 2018, 65, e26832.	0.8	13

#	Article	IF	Citations
37	EPID-08. THE CURRENT LANDSCAPE OF THERAPEUTIC CLINICAL TRIALS IN PEDIATRIC BRAIN TUMORS: A REVIEW OF CLINICALTRIALS.GOV. Neuro-Oncology, 2018, 20, i81-i82.	0.6	0
38	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Childrenâ€™s Oncology Group Randomized ACNS0332 Trial. Journal of Clinical Oncology, 2018, 36, 3388-3395.	0.8	58
39	CRAN-16. IMPORTANCE OF SURGICAL INTERVENTION IN RECOVERY OF VISUAL FUNCTION IN A TEENAGER WITH AN ACIDOPHILIC STEM CELL ADENOMA. Neuro-Oncology, 2018, 20, i39-i40.	0.6	0
40	PDCT-07. FEASIBILITY TRIAL OF TTFIELDS (TUMOR TREATING FIELDS) FOR CHILDREN WITH RECURRENT OR PROGRESSIVE SUPRATENTORIAL HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. Neuro-Oncology, 2018, 20, vi201-vi202.	0.6	4
41	IMMU-09. OUTCOME OF PATIENTS WITH RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TREATED WITH PEMBROLIZUMAB (ANTI-PD-1): A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045). Neuro-Oncology, 2018, 20, i100-i100.	0.6	11
42	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP ACNS0332 TRIAL. Neuro-Oncology, 2018, 20, i68-i69.	0.6	0
43	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. Neuro-Oncology, 2018, 20, i72-i73.	0.6	0
44	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. Neuro-Oncology, 2018, 20, i72-i72.	0.6	4
45	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	3.9	86
46	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	0.6	73
47	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	3.9	271
48	Case-based review: pediatric medulloblastoma. Neuro-Oncology Practice, 2017, 4, 138-150.	1.0	22
49	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Cancer Cell, 2016, 30, 891-908.	7.7	191
50	Treatment of pediatric cerebral radiation necrosis: a systematic review. Journal of Neuro-Oncology, 2016, 130, 141-148.	1.4	26
51	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nature Communications, 2016, 7, 11185.	5.8	197
52	Experimental Therapeutic Trial Design for Pediatric Brain Tumors. Journal of Child Neurology, 2016, 31, 1421-1432.	0.7	0
53	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
54	Handheld Optical Coherence Tomography During Sedation in Young Children With Optic Pathway Gliomas. JAMA Ophthalmology, 2014, 132, 265.	1.4	57

#	Article	IF	Citations
55	Marked Recovery of Vision in Children With Optic Pathway Gliomas Treated With Bevacizumab. JAMA Ophthalmology, 2014, 132, 111.	1.4	100
56	CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathologica, 2014, 128, 291-303.	3.9	141
57	Longâ€term efficacy and toxicity of bevacizumabâ€based therapy in children with recurrent lowâ€grade gliomas. Pediatric Blood and Cancer, 2013, 60, 776-782.	0.8	114
58	Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. Oncotarget, 0, 7, 42837-42842.	0.8	7